According to Associated Press this morning the FDA will move to reclassify marijuana from a Schedule I to a Schedule III drug. Schedule I drugs have a high potential for abuse and no accepted medical use, while Schedule III drugs have a lower potential for abuse and accepted medical uses. The FDA’s plans were confirmed by five sources who spoke on condition of anonymity, but as of April 30 the FDA has made no official comment. The full impact of this change to consumers, retailers, regulators, states, and those serving prison sentences for possession is currently unknown. Here’s a round-up with different perspectives.

DEA Agrees To Reschedule Marijuana Under Federal Law In Historic Move Following Biden-Directed Health Agency’s Recommendation